/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Gain Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$3.45 0.085(8.5%) GANX at 04 Dec 2025 04:32 PM Biotechnology
Lowest Today 2.96
Highest Today 3.365
Today’s Open 2.99
Prev. Close 3.06
52 Week High 3.65
52 Week Low 1.41
Day’s Range: Low 2.96 High 3.365
52-Week Range: Low 1.41 High 3.65
1 day return -
1 Week return -5.15
1 month return +99.39
3 month return +89.14
6 month return +70.61
1 year return +84.4
3 year return -0.3
5 year return -
10 year return -

Institutional Holdings

JONES FINANCIAL COMPANIES LLLP 1.88

Vanguard Group Inc 1.49

Vanguard Institutional Extnd Mkt Idx Tr 1.00

Geode Capital Management, LLC 0.81

Marshall Wace Asset Management Ltd 0.77

Gotham Asset Management, LLC 0.68

CAMBRIDGE Invest RESEARCH ADVISORS, INC. 0.50

Citadel Advisors Llc 0.45

Fidelity Extended Market Index 0.42

BANOR SICAV Rosemary S EUR Acc 0.34

BlackRock Inc 0.31

Northern Trust Corp 0.28

Renaissance Technologies Corp 0.26

Susquehanna International Group, LLP 0.22

Morgan Stanley - Brokerage Accounts 0.21

State Street Corp 0.20

iShares Micro-Cap ETF 0.18

Kovitz Investment Group Partners, LLC 0.13

Dauntless Investment Group, LLC 0.13

Fidelity Total Market Index 0.13

Fidelity Series Total Market Index 0.11

Springbok Capital Management, LLC 0.10

Spartan Extended Market Index Pool F 0.10

Extended Equity Market Fund K 0.10

UBS Group AG 0.09

Bridgeway Capital Management, LLC 0.08

Bridgeway Ultra-Small Company Market 0.08

Northern Trust Extended Eq Market Idx 0.08

NT Ext Equity Mkt Idx Fd - L 0.08

NT Ext Equity Mkt Idx Fd - NL 0.07

Virtu Financial LLC 0.07

Benedict Financial Advisors, INC. 0.06

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.05

Spartan Total Market Index Pool G 0.05

Fidelity Nasdaq Composite Index 0.03

Vanguard U.S. Eq Idx £ Acc 0.03

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.02

NT Ext Eq Mkt Indx Fd DC Lend T3 0.02

1290 VT Micro Cap K 0.02

Extended Equity Market Fund M 0.01

Market Status

Strong Buy: 3

Buy: 4

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 117.69 M

PB Ratio 21.0553

PE Ratio 0.0

Enterprise Value 116.22 M

Total Assets 12.12 M

Volume 981433

Company Financials

Annual Revenue FY23:55180 0.1M, FY22:140108 0.1M, FY21:164994 0.2M, FY20:28881 0.0M, FY19:41301 0.0M

Annual Profit FY23:null 0.0M, FY22:140108 0.1M, FY21:164994 0.2M, FY20:28881 0.0M, FY19:41301 0.0M

Annual Net worth FY23:-22218017 -22.2M, FY22:-17590738 -17.6M, FY21:-13890606 -13.9M, FY20:-3577682 -3.6M, FY19:-2193445 -2.2M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-22817 -0.0M, Q2/2025:-2722297 -2.7M, Q1/2025:-2223099 -2.2M, Q3/2024:null 0.0M, Q2/2024:-20593 -0.0M

Quarterly Net worth Q3/2025:-5284373 -5.3M, Q2/2025:-5809087 -5.8M, Q1/2025:-4530058 -4.5M, Q3/2024:-4485692 -4.5M, Q2/2024:-8143077 -8.1M

Fund house & investment objective

Company Information Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.

Organisation Biotechnology

Employees 23

Industry Biotechnology

CEO Mr. Gene Mack M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow